P510: Predictors of Response and Outcome in Patients With Refractory/Relapsed Acute Myeloid Leukemia Receiving Venetoclax With Non-Intensive Chemotherapy

Abstract

Background:Relapsed/refractory (R/R) acute myeloid leukemia (AML) is a largely unmet medical condition with limited treatment options and dismal prognosis. In newly diagnosed AML patients (pts), a modified risk stratification based on the mutational status of four genes (FLT3-ITD, KRAS, NRAS and TP53) indicated distinct benefit from treatment with azacitidine and venetoclax (Döhner et al. ASH 2022). However, the role of venetoclax (VEN) in R/R AML is not well defined yet and predictors of response are unclear.